List of Tables
Table 1. Global Circular mRNA Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Circular mRNA Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Circular mRNA Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Circular mRNA Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Circular mRNA Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Circular mRNA Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Circular mRNA Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Circular mRNA Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Circular mRNA Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Circular mRNA Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Circular mRNA Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Circular mRNA Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Circular mRNA Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circular mRNA Drugs as of 2024)
Table 16. Global Circular mRNA Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Circular mRNA Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Circular mRNA Drugs Manufacturing Base and Headquarters
Table 19. Global Circular mRNA Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Circular mRNA Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Circular mRNA Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Circular mRNA Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Circular mRNA Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Circular mRNA Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Circular mRNA Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Circular mRNA Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Circular mRNA Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Circular mRNA Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Circular mRNA Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Circular mRNA Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Circular mRNA Drugs Growth Accelerators and Market Barriers
Table 37. North America Circular mRNA Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Circular mRNA Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Circular mRNA Drugs Growth Accelerators and Market Barriers
Table 40. Europe Circular mRNA Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Circular mRNA Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Circular mRNA Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Circular mRNA Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Circular mRNA Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Circular mRNA Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Circular mRNA Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Circular mRNA Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Circular mRNA Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Circular mRNA Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Orna Therapeutics Corporation Information
Table 51. Orna Therapeutics Description and Major Businesses
Table 52. Orna Therapeutics Product Models, Descriptions and Specifications
Table 53. Orna Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Orna Therapeutics Sales Value Proportion by Product in 2024
Table 55. Orna Therapeutics Sales Value Proportion by Application in 2024
Table 56. Orna Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 57. Orna Therapeutics Circular mRNA Drugs SWOT Analysis
Table 58. Orna Therapeutics Recent Developments
Table 59. Chimera Therapeutics Corporation Information
Table 60. Chimera Therapeutics Description and Major Businesses
Table 61. Chimera Therapeutics Product Models, Descriptions and Specifications
Table 62. Chimera Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Chimera Therapeutics Sales Value Proportion by Product in 2024
Table 64. Chimera Therapeutics Sales Value Proportion by Application in 2024
Table 65. Chimera Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 66. Chimera Therapeutics Circular mRNA Drugs SWOT Analysis
Table 67. Chimera Therapeutics Recent Developments
Table 68. CirCode Corporation Information
Table 69. CirCode Description and Major Businesses
Table 70. CirCode Product Models, Descriptions and Specifications
Table 71. CirCode Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. CirCode Sales Value Proportion by Product in 2024
Table 73. CirCode Sales Value Proportion by Application in 2024
Table 74. CirCode Sales Value Proportion by Geographic Area in 2024
Table 75. CirCode Circular mRNA Drugs SWOT Analysis
Table 76. CirCode Recent Developments
Table 77. Therorna Corporation Information
Table 78. Therorna Description and Major Businesses
Table 79. Therorna Product Models, Descriptions and Specifications
Table 80. Therorna Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Therorna Sales Value Proportion by Product in 2024
Table 82. Therorna Sales Value Proportion by Application in 2024
Table 83. Therorna Sales Value Proportion by Geographic Area in 2024
Table 84. Therorna Circular mRNA Drugs SWOT Analysis
Table 85. Therorna Recent Developments
Table 86. Edigene Corporation Information
Table 87. Edigene Description and Major Businesses
Table 88. Edigene Product Models, Descriptions and Specifications
Table 89. Edigene Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Edigene Sales Value Proportion by Product in 2024
Table 91. Edigene Sales Value Proportion by Application in 2024
Table 92. Edigene Sales Value Proportion by Geographic Area in 2024
Table 93. Edigene Circular mRNA Drugs SWOT Analysis
Table 94. Edigene Recent Developments
Table 95. Aikang Pharmaceuticals Corporation Information
Table 96. Aikang Pharmaceuticals Description and Major Businesses
Table 97. Aikang Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Aikang Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Aikang Pharmaceuticals Recent Developments
Table 100. Curemed Bio Corporation Information
Table 101. Curemed Bio Description and Major Businesses
Table 102. Curemed Bio Product Models, Descriptions and Specifications
Table 103. Curemed Bio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Curemed Bio Recent Developments
Table 105. Torque Bio Corporation Information
Table 106. Torque Bio Description and Major Businesses
Table 107. Torque Bio Product Models, Descriptions and Specifications
Table 108. Torque Bio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Torque Bio Recent Developments
Table 110. Sail Biomedicines Corporation Information
Table 111. Sail Biomedicines Description and Major Businesses
Table 112. Sail Biomedicines Product Models, Descriptions and Specifications
Table 113. Sail Biomedicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Sail Biomedicines Recent Developments
Table 115. Orbital Therapeutics Corporation Information
Table 116. Orbital Therapeutics Description and Major Businesses
Table 117. Orbital Therapeutics Product Models, Descriptions and Specifications
Table 118. Orbital Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Orbital Therapeutics Recent Developments
Table 120. Key Raw Materials Distribution
Table 121. Raw Materials Key Suppliers
Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 123. Milestones in Production Technology Evolution
Table 124. Distributors List
Table 125. Market Trends and Market Evolution
Table 126. Market Drivers and Opportunities
Table 127. Market Challenges, Risks, and Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Circular mRNA Drugs Product Picture
Figure 2. Global Circular mRNA Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Preventive Medicine Product Picture
Figure 4. Medicine Product Picture
Figure 5. Global Circular mRNA Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Infectious Disease
Figure 7. Cancer
Figure 8. Others
Figure 9. Circular mRNA Drugs Report Years Considered
Figure 10. Global Circular mRNA Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 12. Global Circular mRNA Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Circular mRNA Drugs Revenue Market Share by Region (2020-2031)
Figure 14. Global Circular mRNA Drugs Sales (2020-2031) & (K Units)
Figure 15. Global Circular mRNA Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Circular mRNA Drugs Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Circular mRNA Drugs Sales Volume Market Share in 2024
Figure 18. Global Circular mRNA Drugs Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Preventive Medicine Revenue Market Share by Manufacturer in 2024
Figure 21. Medicine Revenue Market Share by Manufacturer in 2024
Figure 22. Global Circular mRNA Drugs Sales Market Share by Type (2020-2031)
Figure 23. Global Circular mRNA Drugs Revenue Market Share by Type (2020-2031)
Figure 24. Global Circular mRNA Drugs Sales Market Share by Application (2020-2031)
Figure 25. Global Circular mRNA Drugs Revenue Market Share by Application (2020-2031)
Figure 26. North America Circular mRNA Drugs Sales YoY (2020-2031) & (K Units)
Figure 27. North America Circular mRNA Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Circular mRNA Drugs Sales Revenue (US$ Million) in 2024
Figure 29. North America Circular mRNA Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Circular mRNA Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Circular mRNA Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Circular mRNA Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Circular mRNA Drugs Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Circular mRNA Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Circular mRNA Drugs Sales Revenue (US$ Million) in 2024
Figure 39. Europe Circular mRNA Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Circular mRNA Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Circular mRNA Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Circular mRNA Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. France Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Circular mRNA Drugs Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Circular mRNA Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Circular mRNA Drugs Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Circular mRNA Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Circular mRNA Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Circular mRNA Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Circular mRNA Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. India Circular mRNA Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Circular mRNA Drugs Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Circular mRNA Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Circular mRNA Drugs Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Circular mRNA Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Circular mRNA Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Circular mRNA Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Circular mRNA Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Circular mRNA Drugs Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Circular mRNA Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Circular mRNA Drugs Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Circular mRNA Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Circular mRNA Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Circular mRNA Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Circular mRNA Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Circular mRNA Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Circular mRNA Drugs Industry Chain Mapping
Figure 81. Regional Circular mRNA Drugs Manufacturing Base Distribution (%)
Figure 82. Global Circular mRNA Drugs Production Market Share by Region (2020-2031)
Figure 83. Circular mRNA Drugs Production Process
Figure 84. Regional Circular mRNA Drugs Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed